JP6612874B2 - α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物 - Google Patents

α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物 Download PDF

Info

Publication number
JP6612874B2
JP6612874B2 JP2017533183A JP2017533183A JP6612874B2 JP 6612874 B2 JP6612874 B2 JP 6612874B2 JP 2017533183 A JP2017533183 A JP 2017533183A JP 2017533183 A JP2017533183 A JP 2017533183A JP 6612874 B2 JP6612874 B2 JP 6612874B2
Authority
JP
Japan
Prior art keywords
carboxamide
thiophene
radical
benzo
azaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017533183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538756A (ja
JP2017538756A5 (cg-RX-API-DMAC10.html
Inventor
アチャーリャ ラクシャ
エー. バーネット デュアン
グレゴリー バルサヴィッチ マシュー
サイモン クック アンドリュー
オールデン ハリソン ブライス
ケーニッヒ ゲルハルト
ジェイ. マクライナー アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axovant Sciences GmbH
Original Assignee
Axovant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axovant Sciences GmbH filed Critical Axovant Sciences GmbH
Publication of JP2017538756A publication Critical patent/JP2017538756A/ja
Publication of JP2017538756A5 publication Critical patent/JP2017538756A5/ja
Application granted granted Critical
Publication of JP6612874B2 publication Critical patent/JP6612874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2017533183A 2014-12-16 2015-12-14 α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物 Expired - Fee Related JP6612874B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092702P 2014-12-16 2014-12-16
US62/092,702 2014-12-16
US201562167706P 2015-05-28 2015-05-28
US62/167,706 2015-05-28
PCT/US2015/065497 WO2016100184A1 (en) 2014-12-16 2015-12-14 Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019198132A Division JP2020033371A (ja) 2014-12-16 2019-10-31 α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物

Publications (3)

Publication Number Publication Date
JP2017538756A JP2017538756A (ja) 2017-12-28
JP2017538756A5 JP2017538756A5 (cg-RX-API-DMAC10.html) 2019-01-31
JP6612874B2 true JP6612874B2 (ja) 2019-11-27

Family

ID=56127420

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017533183A Expired - Fee Related JP6612874B2 (ja) 2014-12-16 2015-12-14 α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物
JP2019198132A Pending JP2020033371A (ja) 2014-12-16 2019-10-31 α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019198132A Pending JP2020033371A (ja) 2014-12-16 2019-10-31 α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物

Country Status (8)

Country Link
US (1) US10183938B2 (cg-RX-API-DMAC10.html)
EP (2) EP3623371A1 (cg-RX-API-DMAC10.html)
JP (2) JP6612874B2 (cg-RX-API-DMAC10.html)
AU (1) AU2015362790A1 (cg-RX-API-DMAC10.html)
CA (1) CA2971413A1 (cg-RX-API-DMAC10.html)
ES (1) ES2764660T3 (cg-RX-API-DMAC10.html)
IL (1) IL252931A0 (cg-RX-API-DMAC10.html)
WO (1) WO2016100184A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN107847494A (zh) 2015-06-10 2018-03-27 阿考温特科学股份有限公司 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
JP6784069B2 (ja) * 2015-07-07 2020-11-11 Jnc株式会社 液晶性化合物、液晶組成物および液晶表示素子
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
CN108129430A (zh) * 2016-11-30 2018-06-08 重庆圣华曦药业股份有限公司 一种立他司特中间体的合成方法
BR112018016629A2 (pt) * 2016-12-16 2018-12-26 Univ Vanderbilt moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
MX2021000293A (es) 2018-07-09 2021-07-15 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos.
JP7575952B2 (ja) 2019-01-08 2024-10-30 杏林製薬株式会社 15-pgdh阻害薬
WO2020160151A1 (en) 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
KR20220002890A (ko) 2019-03-19 2022-01-07 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물
BR112022024156A2 (pt) 2020-05-29 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Compostos heterocílicos antelmínticos
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
WO2023073641A1 (en) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds
IL312296A (en) 2021-12-01 2024-06-01 Pfizer 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
AU2023205061A1 (en) 2022-01-10 2024-08-29 Recludix Pharma, Inc. Stat modulators and uses thereof
JP2025507684A (ja) 2022-02-25 2025-03-21 リクルディクス ファーマ, インコーポレイテッド がんおよび炎症状態を処置するための、STAT3およびSTAT6モジュレータとしての6-オキソデカヒドロピロロ[1,2-a][1,5]ジアゾシンおよび6-オキソデカヒドロ-4H-ピロロ[2,1-d][1,5]チアゾシン誘導体
IL316050A (en) 2022-03-31 2024-11-01 Recludix Pharma Inc STAT modulators and their uses
CN117447386A (zh) * 2023-10-26 2024-01-26 甘肃皓天医药科技有限责任公司 一种2-甲基哌啶-5-胺的不对称合成方法
WO2026015868A1 (en) 2024-07-12 2026-01-15 Recludix Pharma, Inc. Stat6 modulators and uses thereof

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666767A (en) 1970-01-28 1972-05-30 Warner Lambert Co 2-amino-1-(2-imidazolin-2-yl)-2-imidazolines
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
TW300219B (cg-RX-API-DMAC10.html) 1991-09-14 1997-03-11 Hoechst Ag
JP2553020B2 (ja) 1991-11-07 1996-11-13 吉富製薬株式会社 キヌクリジン化合物およびその医薬用途
FR2730995B1 (fr) 1995-02-23 1997-04-04 Cird Galderma Composes bi-aromatiques derives d'amide, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
US6225310B1 (en) 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6727070B2 (en) 2000-02-14 2004-04-27 The Board Of Regents, The University Of Texas System Protein/solubility folding assessed by structural complementation
AU2001241056A1 (en) 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
WO2002000222A1 (en) 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for the treatment of cancer
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
CZ2004408A3 (cs) 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
EP1453792B1 (en) 2001-11-19 2007-04-18 Elan Pharmaceuticals, Inc. Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease
US20030109519A1 (en) 2001-11-30 2003-06-12 Jeppe Sturis Use of selective potassium channel openers
US20030125323A1 (en) 2001-11-30 2003-07-03 Jeppe Sturis Use of selective potassium channel openers
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20040192594A1 (en) 2002-01-28 2004-09-30 Paul Reid Modified neurotoxins as therapeutic agents for the treatment of diseases and methods of making
JP2003267977A (ja) 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
MXPA04009541A (es) 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US20030235583A1 (en) 2002-06-14 2003-12-25 Jeppe Sturis Combined use of a modulator of CD3 and a beta cell resting compound
MXPA05000754A (es) 2002-07-17 2005-04-19 Warner Lambert Co Combinacion de un inhibidor carboxilico alosterico de la metaloproteinasa de matriz-13 con celecoxib o valdecoxib.
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
WO2004013137A1 (en) 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
MXPA05001702A (es) 2002-08-14 2005-04-19 Neurosearch As Derivados de quinuclidina novedosos y su uso.
PL374946A1 (en) 2002-09-05 2005-11-14 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
BR0315056A (pt) 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
AU2003279492A1 (en) * 2002-12-11 2004-06-30 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
RU2339624C2 (ru) 2002-12-12 2008-11-27 Авентис Фарма С.А. Производные аминоиндазолов и их применение в качестве ингибиторов киназ
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
WO2005016923A1 (en) 2003-08-13 2005-02-24 Neurosearch A/S Novel quinuclidine derivatives and their pharmaceutical use
EP1682126B1 (en) 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as inhibitors of raf kinase
US7241773B2 (en) 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
US20050239853A1 (en) 2004-02-04 2005-10-27 Tjeerd Barf New compounds
ATE437880T1 (de) 2004-02-04 2009-08-15 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
DE602005024677D1 (de) 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
AU2005247929B2 (en) 2004-05-24 2010-03-11 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
CA2584836A1 (en) 2004-10-15 2006-04-20 Neurosearch A/S Novel azabicyclic aryl derivatives and their medical use
US20070082350A1 (en) 2005-02-09 2007-04-12 Philip Landfield Assay and method for diagnosing and treating alzheimer's disease
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
PE20070823A1 (es) 2005-11-15 2007-08-09 Glaxo Group Ltd Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
TW200734338A (en) 2006-01-16 2007-09-16 Organon Nv 6-Phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
NZ573735A (en) 2006-05-19 2011-10-28 Abbott Lab Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
MX2008016338A (es) 2006-06-27 2009-01-16 Abbott Lab Derivados de pirrol y sus metodos de uso.
CA2659762A1 (en) 2006-06-27 2008-01-03 Abbott Laboratories Thiazoline and oxazoline derivatives and their methods of use
ITMI20061279A1 (it) 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
CL2008000597A1 (es) 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
CL2008000596A1 (es) 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
EP2497771A1 (en) 2007-03-23 2012-09-12 Abbott Laboratories 4 -substituted azaadamantane derivatives and methods of use thereof
MX2009010175A (es) 2007-03-23 2009-10-12 Abbott Lab Derivados de acetamida y carboxamida de aza-adamantano y metodos de uso de los mismos.
EP2129672B1 (en) 2007-03-23 2011-05-18 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
EP2129673B1 (en) 2007-03-23 2013-11-06 AbbVie Inc. Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
WO2009030716A1 (en) 2007-09-06 2009-03-12 Glaxo Group Limited Piperazine derivative having affinity for the histamine h3 receptor
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
US20090099099A1 (en) 2007-10-16 2009-04-16 Hong Wang Isoflavone Glycosides as Peroxisome Proliferator-Activated Receptor-alpha Modulator
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
MX2010005650A (es) 2007-11-21 2010-06-02 Abbott Lab Derivados de diazabicicloalcano substituidos con biarilo.
CA2705296A1 (en) 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
GB0800035D0 (en) 2008-01-02 2008-02-13 Glaxo Group Ltd Compounds
US8536221B2 (en) 2008-02-07 2013-09-17 Abbvie Inc. Amide derivatives as positive allosteric modulators and methods of use thereof
US7786171B2 (en) 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
WO2009137492A1 (en) 2008-05-05 2009-11-12 Abbott Laboratories Heteroaryl-fused macrocyclic pyrimidine derivatives
US20110189280A1 (en) 2008-08-29 2011-08-04 Allan James Clarke Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof
CN102209540A (zh) 2008-11-11 2011-10-05 塔加西普特公司 使用α7-选择性配体的治疗方法
WO2010145208A1 (en) 2009-06-19 2010-12-23 Abbott Laboratories Diazahomoadamantane derivatives and methods of use thereof
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α7活化劑之用途
ES2512727T3 (es) 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
CN102666540A (zh) 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
US8507516B2 (en) 2009-10-28 2013-08-13 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
TW201144303A (en) 2010-02-17 2011-12-16 Janssen Pharmaceutica Nv Aminothiazolones as estrogen related receptor-α modulators
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基-雜芳基衍生物及其使用方法
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
ES2524892T3 (es) 2010-09-02 2014-12-15 Glaxosmithkline Intellectual Property Development Limited 2-(Benciloxi)benzamidas como inhibidores de LRRK2 quinasa
EP2619205B1 (en) 2010-09-23 2017-05-17 AbbVie Bahamas Ltd. Monohydrate of an azaadamantane derivative
FR2966827B1 (fr) 2010-10-27 2014-08-22 Kimonella Ventures Ltd Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
EP2640378A4 (en) 2010-11-18 2014-05-21 Envivo Pharmaceuticals Inc INFLAMMATION TREATMENT WITH CERTAIN NICOTINIC ACID ALPHA-7 RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS
EP2670744B1 (en) 2011-02-03 2015-05-27 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
JP2014076948A (ja) 2011-02-09 2014-05-01 Astellas Pharma Inc イソキノリンアミド誘導体
AU2012221800B2 (en) 2011-02-23 2016-10-27 Lupin Limited Heteroaryl derivatives as alpha7 nAChR modulators
AU2012235779B2 (en) 2011-03-31 2017-03-02 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease
ES2606043T3 (es) 2011-07-05 2017-03-17 Lupin Limited Derivados de biarilo como moduladores de nAChR
WO2013132380A1 (en) 2012-03-06 2013-09-12 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
US9458179B2 (en) 2012-05-24 2016-10-04 Bristol-Myers Squibb Company Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
WO2014072957A1 (en) 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
WO2014083003A1 (en) 2012-11-27 2014-06-05 Shire International Gmbh Pro-cognitive compound
BR112015013771B1 (pt) 2012-12-11 2022-10-04 Novartis Ag Composição que compreende um ativador do receptor alfa 7, nicotínico de acetilcolina (nachr) como biomarcador preditivo de resposta ao tratamento de ativador do dito receptor
US9617211B2 (en) 2013-01-16 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
TR201904614T4 (en) 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
US9617210B2 (en) 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
WO2014203150A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
WO2015066371A1 (en) 2013-10-31 2015-05-07 Forum Pharmaceuticals, Inc. SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors

Also Published As

Publication number Publication date
US20170369486A1 (en) 2017-12-28
IL252931A0 (en) 2017-08-31
US10183938B2 (en) 2019-01-22
EP3623371A1 (en) 2020-03-18
EP3233087A4 (en) 2018-05-30
WO2016100184A1 (en) 2016-06-23
JP2017538756A (ja) 2017-12-28
JP2020033371A (ja) 2020-03-05
EP3233087B1 (en) 2019-10-02
CA2971413A1 (en) 2016-06-23
EP3233087A1 (en) 2017-10-25
ES2764660T3 (es) 2020-06-04
AU2015362790A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
US10183938B2 (en) Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
WO2015066371A1 (en) SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
CA2710234C (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2866201C (en) Tetrahydropyrrolothiazine compounds
CA3094305A1 (en) Brm targeting compounds and associated methods of use
CA3095646A1 (en) Benzothiophenes and related compounds as sting agonists
CA2871650A1 (en) Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
TWI402272B (zh) 作為血清素5-HT2c受體配位體之噻吩基及吡咯基氮呯及其用途
CA3114918A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
WO2000039086A1 (en) Aromatic heterocycle compounds having hiv integrase inhibiting activities
WO2020031107A1 (en) Chemical compounds
CA3110237A1 (en) Cardiac sarcomere inhibitors
CA2970537A1 (en) Tricyclic imidazo-pyrimidinone compounds for the mediation of lipoprotein-associated phospholipase a2
NO312676B1 (no) Azabisyklisk substituerte tiadiazolforbindelser, fremgangsmåte for fremstilling derav, farmasöytiske preparater oganvendelse av forbindelsene til fremstilling av medikamenter
CA3188446A1 (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
US20170247393A1 (en) Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors
TW202136253A (zh) Trpml調節劑
JPWO2007091570A1 (ja) スフィンゴシン−1−リン酸結合阻害物質
CA2957544A1 (en) Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
CA3218724A1 (en) 3-pyrrolylsulfonamide compounds as gpr17 antagonists
CA3011201C (en) 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
CN120641397A (zh) 稠合吡咯基磺酰胺化合物
TW201441233A (zh) 作爲β-分泌酶抑制劑之稠合多環的碸化合物及其使用方法
EA020010B1 (ru) БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 РЕЦЕПТОРОВ
US20070185144A1 (en) Beta-secretase modulators and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191031

R150 Certificate of patent or registration of utility model

Ref document number: 6612874

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees